Point taken about execution failure.
But the design is fine.
Open label means that patients don't have to worry about being on placebo.
The two dosage levels means that patients can choose which they prefer.
The problems are that EMD AML is a very rare disease, and sites other than Newcastle haven't appeared.
General Comments / Chat, page-7684
-
-
- There are more pages in this discussion • 3,545 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M |
Open | High | Low | Value | Volume |
$1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5700 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 296 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5700 | 1.550 |
2 | 1629 | 1.545 |
1 | 1500 | 1.540 |
1 | 3000 | 1.515 |
2 | 8500 | 1.510 |
Price($) | Vol. | No. |
---|---|---|
1.585 | 296 | 1 |
1.590 | 2500 | 1 |
1.620 | 2050 | 1 |
1.650 | 4677 | 2 |
1.660 | 500 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online